Skip to main content
Erschienen in: Drugs & Aging 7/2008

01.07.2008 | Review Article

Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia

verfasst von: Dr Félix Gutiérrez, Mar Masiá

Erschienen in: Drugs & Aging | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in elderly patients. Therefore, efforts to optimize the healthcare process for patients with CAP are warranted. An organized approach to management is likely to improve clinical results. Assessing the severity of CAP is crucial to predicting outcome, deciding the site of care, and selecting appropriate empirical therapy. Unfortunately, current prognostic scoring systems for CAP such as CURB-65 (confusion, uraemia, respiratory rate, low blood pressure and 65 years of age) or the Pneumonia Severity Index have not been validated specifically in older adults, in whom assessment of mortality risk alone might not be adequate for predicting outcomes.
Obtaining a microbial diagnosis remains problematic and may be particularly challenging in frail elderly persons, who may have greater difficulties producing sputum. Effective empirical treatment involves selection of a regimen with a spectrum of activity that includes the causative pathogen. Although most cases of CAP are probably caused by a single pathogen, dual and multiple infections are increasingly being reported. Streptococcus pneumoniae remains the overriding aetiological agent, particularly in very elderly people. However, respiratory viruses and ‘atypical’ organisms such as Chlamydia pneumoniae are being described with increasing frequency in old patients, and aspiration pneumonia should also be taken into consideration, particularly in very elderly subjects and those with dementia. Age >65 years is a well established risk factor for infection with drug-resistant S. pneumoniae. Clinicians should be aware of additional risk factors for acquiring less common pathogens or antibacterial-resistant organisms that may suggest that additions or modifications to the basic empirical regimen are warranted. In addition to administration of antibacterials, appropriate supportive therapy, covering management of severe sepsis and septic shock, respiratory failure, as well as management of any decompensated underlying disease, may be critical to improving outcomes in elderly patients with CAP. Immunization with pneumococcal and influenza vaccines has also been demonstrated to be beneficial in numerous large studies.
There is good evidence that implementation of guidelines leads to improvement in clinical outcomes in elderly patients with CAP, including a reduction in mortality. Protocols should address a comprehensive set of elements in the process of care and should periodically be evaluated to measure their effects on clinically relevant outcomes. Assessment of functional clinical outcome variables, in addition to survival, is strongly recommended for this population.
Literatur
1.
Zurück zum Zitat Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–72PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–72PubMedCrossRef
2.
Zurück zum Zitat Niederman MS, McCombs J, Unger A, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–36PubMedCrossRef Niederman MS, McCombs J, Unger A, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–36PubMedCrossRef
3.
Zurück zum Zitat Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–9PubMedCrossRef Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–9PubMedCrossRef
4.
Zurück zum Zitat Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006; 53: 166–74PubMedCrossRef Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006; 53: 166–74PubMedCrossRef
5.
Zurück zum Zitat Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642–50PubMedCrossRef Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642–50PubMedCrossRef
6.
Zurück zum Zitat May DS, Kelly JJ, Mendlein JM, et al. Surveillance of major causes of hospitalization among the elderly, 1988. MMWR Morb Mortal Wkly Rep 1991; 40: 7–21 May DS, Kelly JJ, Mendlein JM, et al. Surveillance of major causes of hospitalization among the elderly, 1988. MMWR Morb Mortal Wkly Rep 1991; 40: 7–21
8.
9.
Zurück zum Zitat Torres A, El-Ebiary M, Riquelme R, et al. Community-acquired pneumonia in the elderly. Semin Respir Infect 1999; 14: 173–83PubMed Torres A, El-Ebiary M, Riquelme R, et al. Community-acquired pneumonia in the elderly. Semin Respir Infect 1999; 14: 173–83PubMed
10.
Zurück zum Zitat Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 2004; 21: 851–64PubMedCrossRef Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 2004; 21: 851–64PubMedCrossRef
11.
Zurück zum Zitat Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313–20PubMedCrossRef Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313–20PubMedCrossRef
12.
Zurück zum Zitat Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000; 94: 422–7PubMedCrossRef Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000; 94: 422–7PubMedCrossRef
13.
Zurück zum Zitat Chi RC, Jackson LA, Neuzil KM. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. J Am Geriatr Soc 2006; 54: 115–20PubMedCrossRef Chi RC, Jackson LA, Neuzil KM. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. J Am Geriatr Soc 2006; 54: 115–20PubMedCrossRef
14.
Zurück zum Zitat Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993; 137: 977–88PubMed Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993; 137: 977–88PubMed
16.
Zurück zum Zitat Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50PubMedCrossRef Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50PubMedCrossRef
17.
Zurück zum Zitat Fernández-Sabé N, Carratalá J, Rosón B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics and outcomes. Medicine (Baltimore) 2003; 82: 159–69 Fernández-Sabé N, Carratalá J, Rosón B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics and outcomes. Medicine (Baltimore) 2003; 82: 159–69
18.
Zurück zum Zitat Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766–72PubMed Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766–72PubMed
19.
Zurück zum Zitat Gutiérrez F, Masiá M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia at the dawn of the twenty first century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005; 11: 788–800PubMedCrossRef Gutiérrez F, Masiá M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia at the dawn of the twenty first century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005; 11: 788–800PubMedCrossRef
20.
Zurück zum Zitat Clemente MG, Budino TG, Seco GA, et al. Community-acquired pneumonia in the elderly: prognostic factors [in Spanish]. Arch Bronconeumol 2002; 38: 67–71PubMed Clemente MG, Budino TG, Seco GA, et al. Community-acquired pneumonia in the elderly: prognostic factors [in Spanish]. Arch Bronconeumol 2002; 38: 67–71PubMed
21.
Zurück zum Zitat Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20: 14–9PubMed Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20: 14–9PubMed
22.
Zurück zum Zitat Riquelme R, Torres A, El-Elbiary M, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450–5PubMed Riquelme R, Torres A, El-Elbiary M, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450–5PubMed
23.
Zurück zum Zitat Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 59: 1550–5CrossRef Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 59: 1550–5CrossRef
24.
Zurück zum Zitat Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man’s friend? Arch Intern Med 2003; 163: 317–23PubMedCrossRef Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man’s friend? Arch Intern Med 2003; 163: 317–23PubMedCrossRef
25.
Zurück zum Zitat Torres OH, Munoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc 2004; 52: 1603–9PubMedCrossRef Torres OH, Munoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc 2004; 52: 1603–9PubMedCrossRef
26.
Zurück zum Zitat Conte HA, Chen YT, Mehal W, et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 1999; 106: 20–8PubMedCrossRef Conte HA, Chen YT, Mehal W, et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 1999; 106: 20–8PubMedCrossRef
27.
Zurück zum Zitat Ewig S, Kleinfeld T, Bauer T, et al. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999; 14: 370–5PubMedCrossRef Ewig S, Kleinfeld T, Bauer T, et al. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999; 14: 370–5PubMedCrossRef
28.
Zurück zum Zitat Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community-acquired pneumonia: a case controlled study of patients aged ≥75 yrs. Eur Respir J 2001; 17: 200–5PubMedCrossRef Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community-acquired pneumonia: a case controlled study of patients aged ≥75 yrs. Eur Respir J 2001; 17: 200–5PubMedCrossRef
29.
Zurück zum Zitat Rello J, Rodriguez R, Jubert P, et al., and the Study Group for Severe Community-acquired Pneumonia. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis 1996; 23: 723–8PubMedCrossRef Rello J, Rodriguez R, Jubert P, et al., and the Study Group for Severe Community-acquired Pneumonia. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis 1996; 23: 723–8PubMedCrossRef
30.
Zurück zum Zitat Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007; 131: 1205–15PubMedCrossRef Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007; 131: 1205–15PubMedCrossRef
31.
Zurück zum Zitat Dean NC, Bateman KA, Donnelly SM, et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006 Sep; 130(3): 794–9PubMedCrossRef Dean NC, Bateman KA, Donnelly SM, et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006 Sep; 130(3): 794–9PubMedCrossRef
32.
Zurück zum Zitat Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451–7PubMedCrossRef Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451–7PubMedCrossRef
33.
Zurück zum Zitat Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators: Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749–55PubMedCrossRef Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators: Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749–55PubMedCrossRef
34.
Zurück zum Zitat Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004; 39: 955–63PubMedCrossRef Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004; 39: 955–63PubMedCrossRef
35.
Zurück zum Zitat Mortensen EM, Restrepo M, Anzueto A, et al. Effects of guideline concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726–31PubMedCrossRef Mortensen EM, Restrepo M, Anzueto A, et al. Effects of guideline concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726–31PubMedCrossRef
36.
Zurück zum Zitat Meehan TP, Weingarten SR, Holmboe ES, et al. A statewide initiative to improve the care of hospitalized pneumonia patients: the Connecticut Pneumonia Pathway Project. Am J Med 2001; 111: 203–10PubMedCrossRef Meehan TP, Weingarten SR, Holmboe ES, et al. A statewide initiative to improve the care of hospitalized pneumonia patients: the Connecticut Pneumonia Pathway Project. Am J Med 2001; 111: 203–10PubMedCrossRef
37.
Zurück zum Zitat Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care–associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854–62PubMedCrossRef Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care–associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854–62PubMedCrossRef
38.
Zurück zum Zitat Niederman MS, Craven DE, Bonten MJ, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416CrossRef Niederman MS, Craven DE, Bonten MJ, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416CrossRef
39.
Zurück zum Zitat Hiramatsu K, Niederman MS. Health-care-associated pneumonia: a new therapeutic paradigm. Chest 2005; 128: 3784–7PubMedCrossRef Hiramatsu K, Niederman MS. Health-care-associated pneumonia: a new therapeutic paradigm. Chest 2005; 128: 3784–7PubMedCrossRef
40.
Zurück zum Zitat Mylotte JM. Nursing home-acquired pneumonia: update on treatment options. Drugs Aging 2006; 23: 377–90PubMedCrossRef Mylotte JM. Nursing home-acquired pneumonia: update on treatment options. Drugs Aging 2006; 23: 377–90PubMedCrossRef
41.
Zurück zum Zitat Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82PubMedCrossRef Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82PubMedCrossRef
42.
Zurück zum Zitat Juthani-Mehta M, Quagliarello V. Prognostic scoring systems for infectious diseases: their applicability to the care of older adults. Clin Infect Dis 2004; 38: 692–6PubMedCrossRef Juthani-Mehta M, Quagliarello V. Prognostic scoring systems for infectious diseases: their applicability to the care of older adults. Clin Infect Dis 2004; 38: 692–6PubMedCrossRef
43.
Zurück zum Zitat Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patient’s outcome research team pneumonia severity index. Chest 2005; 128: 2223–9PubMedCrossRef Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patient’s outcome research team pneumonia severity index. Chest 2005; 128: 2223–9PubMedCrossRef
44.
Zurück zum Zitat Mirete C, Gutiérrez F, Masiá M, et al. Usefulness of acute-phase proteins in community-acquired pneumonia [in Spanish]. Med Clin (Barc) 2004; 122: 245–7CrossRef Mirete C, Gutiérrez F, Masiá M, et al. Usefulness of acute-phase proteins in community-acquired pneumonia [in Spanish]. Med Clin (Barc) 2004; 122: 245–7CrossRef
45.
Zurück zum Zitat Masiá M, Gutiérrez F, Llorca B, et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004; 50: 1661–4PubMedCrossRef Masiá M, Gutiérrez F, Llorca B, et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004; 50: 1661–4PubMedCrossRef
46.
Zurück zum Zitat Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84–93PubMedCrossRef Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84–93PubMedCrossRef
47.
Zurück zum Zitat Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68–73PubMedCrossRef Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68–73PubMedCrossRef
48.
Zurück zum Zitat Brunkhorst FM, Al-Nawas B, Krummenauer F, et al. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002; 8: 93–100PubMedCrossRef Brunkhorst FM, Al-Nawas B, Krummenauer F, et al. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002; 8: 93–100PubMedCrossRef
49.
Zurück zum Zitat Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005: 258; 391–3PubMedCrossRef Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005: 258; 391–3PubMedCrossRef
50.
Zurück zum Zitat Christ-Crain M, Morgenthaler NG, Stolz D, et al. Proadre-nomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96PubMedCrossRef Christ-Crain M, Morgenthaler NG, Stolz D, et al. Proadre-nomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96PubMedCrossRef
51.
Zurück zum Zitat Masia M, Papassotiriou J, Morgenthaler N, et al. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007 Dec; 53(12): 2193–201PubMedCrossRef Masia M, Papassotiriou J, Morgenthaler N, et al. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007 Dec; 53(12): 2193–201PubMedCrossRef
52.
Zurück zum Zitat Suchyta MR, Dean NC, Narus S, et al. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 2001; 110: 306–9PubMedCrossRef Suchyta MR, Dean NC, Narus S, et al. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 2001; 110: 306–9PubMedCrossRef
53.
Zurück zum Zitat Arnold FW, Ramirez JA, McDonald LC, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 2003; 124: 121–4PubMedCrossRef Arnold FW, Ramirez JA, McDonald LC, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 2003; 124: 121–4PubMedCrossRef
54.
Zurück zum Zitat Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 2003; 124: 2148–55PubMedCrossRef Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 2003; 124: 2148–55PubMedCrossRef
55.
Zurück zum Zitat Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998; 12: 741–59PubMedCrossRef Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998; 12: 741–59PubMedCrossRef
56.
Zurück zum Zitat Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004; 32: 2398–402PubMedCrossRef Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004; 32: 2398–402PubMedCrossRef
57.
Zurück zum Zitat Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717–23PubMedCrossRef Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717–23PubMedCrossRef
58.
Zurück zum Zitat Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158–65PubMedCrossRef Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158–65PubMedCrossRef
59.
Zurück zum Zitat El Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163: 645–51PubMed El Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163: 645–51PubMed
60.
Zurück zum Zitat Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118: 1344–54PubMedCrossRef Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118: 1344–54PubMedCrossRef
61.
Zurück zum Zitat Meehan TP, Chua-Reyes JM, Tate J, et al. Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 2000; 117: 1378–85PubMedCrossRef Meehan TP, Chua-Reyes JM, Tate J, et al. Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 2000; 117: 1378–85PubMedCrossRef
62.
Zurück zum Zitat Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54PubMed Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54PubMed
63.
Zurück zum Zitat Ely EW, Evans GW, Haponik EF. Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit. Ann Intern Med 1999; 131: 96–104PubMed Ely EW, Evans GW, Haponik EF. Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit. Ann Intern Med 1999; 131: 96–104PubMed
64.
Zurück zum Zitat Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453–9PubMedCrossRef Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453–9PubMedCrossRef
65.
Zurück zum Zitat Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27: 358–63PubMedCrossRef Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27: 358–63PubMedCrossRef
66.
Zurück zum Zitat van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672–8PubMedCrossRef van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672–8PubMedCrossRef
67.
Zurück zum Zitat Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179–84PubMedCrossRef Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179–84PubMedCrossRef
68.
Zurück zum Zitat Gutiérrez F, Masiá M, Rodriguez JC, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005; 24: 377–83PubMedCrossRef Gutiérrez F, Masiá M, Rodriguez JC, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005; 24: 377–83PubMedCrossRef
69.
Zurück zum Zitat Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β -lactam based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 396–8CrossRef Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β -lactam based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 396–8CrossRef
70.
Zurück zum Zitat Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837–42PubMedCrossRef Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837–42PubMedCrossRef
71.
Zurück zum Zitat Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39: 165–9PubMedCrossRef Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39: 165–9PubMedCrossRef
72.
Zurück zum Zitat Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987; 25: 758–62PubMed Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987; 25: 758–62PubMed
73.
Zurück zum Zitat Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31: 869–74PubMedCrossRef Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31: 869–74PubMedCrossRef
74.
Zurück zum Zitat Gleckman R, DeVita J, Hibert D, et al. Sputum gram stain assessment in community-acquired bacteremic pneumonia. J Clin Microbiol 1988; 26: 846–9PubMed Gleckman R, DeVita J, Hibert D, et al. Sputum gram stain assessment in community-acquired bacteremic pneumonia. J Clin Microbiol 1988; 26: 846–9PubMed
75.
Zurück zum Zitat Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164: 1807–11PubMedCrossRef Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164: 1807–11PubMedCrossRef
76.
Zurück zum Zitat Reed WW, Byrd GS, Gates Jr RH, et al. Sputum gram’s stain in community-acquired pneumococcal pneumonia: a meta-analysis. West J Med 1996; 165: 197–204PubMed Reed WW, Byrd GS, Gates Jr RH, et al. Sputum gram’s stain in community-acquired pneumococcal pneumonia: a meta-analysis. West J Med 1996; 165: 197–204PubMed
77.
Zurück zum Zitat Thorsteinsson SB, Musher DM, Fagan T. The diagnostic value of sputum cultures in acute pneumonia. JAMA 1975; 233: 894–5PubMedCrossRef Thorsteinsson SB, Musher DM, Fagan T. The diagnostic value of sputum cultures in acute pneumonia. JAMA 1975; 233: 894–5PubMedCrossRef
78.
Zurück zum Zitat Gutiéirrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36: 286–92CrossRef Gutiéirrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36: 286–92CrossRef
79.
Zurück zum Zitat Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39: 3495–8PubMedCrossRef Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39: 3495–8PubMedCrossRef
80.
Zurück zum Zitat Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial Legionnaires’ disease. J Clin Microbiol 2003; 41: 838–40PubMedCrossRef Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial Legionnaires’ disease. J Clin Microbiol 2003; 41: 838–40PubMedCrossRef
81.
Zurück zum Zitat Rosóin B, Fernáindez-Sabe N, Carratalá J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38: 222–6CrossRef Rosóin B, Fernáindez-Sabe N, Carratalá J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38: 222–6CrossRef
83.
Zurück zum Zitat Helbig JH, Uldum SA, Luck PC, et al. Detection of Legionella pneumophila antigen in urine samples by the Binax NOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol 2001; 50: 509–16PubMed Helbig JH, Uldum SA, Luck PC, et al. Detection of Legionella pneumophila antigen in urine samples by the Binax NOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol 2001; 50: 509–16PubMed
84.
Zurück zum Zitat Yzerman EP, den Boer JW, Lettinga KD, et al. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires’ disease in the Netherlands. J Clin Microbiol 2002; 40: 3232–6PubMedCrossRef Yzerman EP, den Boer JW, Lettinga KD, et al. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires’ disease in the Netherlands. J Clin Microbiol 2002; 40: 3232–6PubMedCrossRef
85.
Zurück zum Zitat Mirete C, Gutiérrez F, Rodriguez JC, et al. Etiology of community-acquired pneumonia in ambulatory patients: usefulness of a diagnostic investigation protocol using detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples. Med Clin (Barc) 2001; 117: 657–9 Mirete C, Gutiérrez F, Rodriguez JC, et al. Etiology of community-acquired pneumonia in ambulatory patients: usefulness of a diagnostic investigation protocol using detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples. Med Clin (Barc) 2001; 117: 657–9
86.
Zurück zum Zitat Bellei N, Benfica D, Perosa AH, et al. Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment. J Virol Methods 2003; 109: 85–8PubMedCrossRef Bellei N, Benfica D, Perosa AH, et al. Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment. J Virol Methods 2003; 109: 85–8PubMedCrossRef
87.
Zurück zum Zitat Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119: 243–9PubMedCrossRef Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119: 243–9PubMedCrossRef
88.
Zurück zum Zitat Rodriguez JC, Masiá M, Gutiérrez F, et al. Legionella pneumophila in community acquired pneumonia: interpretation of microbiological techniques [in Spanish]. Med Clin (Barc) 2004; 122: 277–8CrossRef Rodriguez JC, Masiá M, Gutiérrez F, et al. Legionella pneumophila in community acquired pneumonia: interpretation of microbiological techniques [in Spanish]. Med Clin (Barc) 2004; 122: 277–8CrossRef
89.
Zurück zum Zitat den Boer JW, Yzerman EP, Schellekens J, et al. A large outbreak of Legionnaires’ disease at a flower show, the Netherlands, 1999. Emerg Infect Dis 2002; 8: 37–43CrossRef den Boer JW, Yzerman EP, Schellekens J, et al. A large outbreak of Legionnaires’ disease at a flower show, the Netherlands, 1999. Emerg Infect Dis 2002; 8: 37–43CrossRef
90.
Zurück zum Zitat Garcia-Fulgueiras A, Navarro C, Fenoll D, et al. Legionnaires’ disease outbreak in Murcia, Spain. Emerg Infect Dis 2003; 9: 915–21PubMedCrossRef Garcia-Fulgueiras A, Navarro C, Fenoll D, et al. Legionnaires’ disease outbreak in Murcia, Spain. Emerg Infect Dis 2003; 9: 915–21PubMedCrossRef
91.
Zurück zum Zitat Benkel DH, McClure EM, Woolard D, et al. Outbreak of Legionnaires’ disease associated with a display whirlpool spa. Int J Epidemiol 2000; 29: 1092–8PubMedCrossRef Benkel DH, McClure EM, Woolard D, et al. Outbreak of Legionnaires’ disease associated with a display whirlpool spa. Int J Epidemiol 2000; 29: 1092–8PubMedCrossRef
92.
Zurück zum Zitat Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol 1999; 14: 191–7PubMedCrossRef Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol 1999; 14: 191–7PubMedCrossRef
93.
Zurück zum Zitat Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160: 3243–7PubMedCrossRef Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160: 3243–7PubMedCrossRef
94.
Zurück zum Zitat Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003; 123: 1142–50PubMedCrossRef Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003; 123: 1142–50PubMedCrossRef
95.
Zurück zum Zitat Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001; 95: 78–82PubMedCrossRef Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001; 95: 78–82PubMedCrossRef
96.
Zurück zum Zitat Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164: 637–44PubMedCrossRef Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164: 637–44PubMedCrossRef
97.
Zurück zum Zitat Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230–7PubMedCrossRef Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230–7PubMedCrossRef
98.
Zurück zum Zitat Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–74PubMedCrossRef Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–74PubMedCrossRef
99.
Zurück zum Zitat Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000; 15: 85–90PubMedCrossRef Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000; 15: 85–90PubMedCrossRef
100.
Zurück zum Zitat Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160: 923–9PubMed Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160: 923–9PubMed
101.
Zurück zum Zitat Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24: 779–85PubMedCrossRef Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24: 779–85PubMedCrossRef
102.
Zurück zum Zitat Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169: 342–7PubMedCrossRef Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169: 342–7PubMedCrossRef
103.
Zurück zum Zitat Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397–405PubMed Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397–405PubMed
104.
Zurück zum Zitat Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of non-invasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585–91PubMed Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of non-invasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585–91PubMed
105.
Zurück zum Zitat Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492–503PubMedCrossRef Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492–503PubMedCrossRef
106.
Zurück zum Zitat Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41: 345–51PubMedCrossRef Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41: 345–51PubMedCrossRef
107.
Zurück zum Zitat Bartlett JG. Diagnostic test for etiologic agents of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 809–27PubMedCrossRef Bartlett JG. Diagnostic test for etiologic agents of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 809–27PubMedCrossRef
108.
Zurück zum Zitat Jimenez P, Saldias F, Meneses M, et al. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia: comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993; 103: 1023–7PubMedCrossRef Jimenez P, Saldias F, Meneses M, et al. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia: comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993; 103: 1023–7PubMedCrossRef
109.
Zurück zum Zitat Zalacain R, Llorente JL, Gaztelurrutia L, et al. Influence of three factors on the diagnostic effectiveness of transthoracic needle aspiration in pneumonia. Chest 1995; 107: 96–100PubMedCrossRef Zalacain R, Llorente JL, Gaztelurrutia L, et al. Influence of three factors on the diagnostic effectiveness of transthoracic needle aspiration in pneumonia. Chest 1995; 107: 96–100PubMedCrossRef
110.
Zurück zum Zitat Scott JA, Hall AJ. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest 1999; 116: 1716–32PubMedCrossRef Scott JA, Hall AJ. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest 1999; 116: 1716–32PubMedCrossRef
111.
Zurück zum Zitat Ishida T, Hashimoto T, Arita M, et al. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med 2001; 40: 873–7PubMedCrossRef Ishida T, Hashimoto T, Arita M, et al. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med 2001; 40: 873–7PubMedCrossRef
112.
Zurück zum Zitat Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154–60PubMed Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154–60PubMed
113.
Zurück zum Zitat van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241–9PubMedCrossRef van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241–9PubMedCrossRef
114.
Zurück zum Zitat Wimberley N, Faling LJ, Bartlett JG. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 1979; 119: 337–43PubMed Wimberley N, Faling LJ, Bartlett JG. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 1979; 119: 337–43PubMed
115.
Zurück zum Zitat Bartlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med 1987; 8: 119–34PubMed Bartlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med 1987; 8: 119–34PubMed
116.
Zurück zum Zitat Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–4PubMedCrossRef Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–4PubMedCrossRef
117.
Zurück zum Zitat Benenson R, Magalski A, Cavanaugh S, et al. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med 1999; 6: 1243–8PubMedCrossRef Benenson R, Magalski A, Cavanaugh S, et al. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med 1999; 6: 1243–8PubMedCrossRef
118.
Zurück zum Zitat Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127: 1260–70PubMedCrossRef Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127: 1260–70PubMedCrossRef
119.
Zurück zum Zitat Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330–5PubMedCrossRef Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330–5PubMedCrossRef
120.
121.
Zurück zum Zitat Falguera M, Sacristan O, Nogues A, et al. Nonsevere community acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001; 161: 1866–72PubMedCrossRef Falguera M, Sacristan O, Nogues A, et al. Nonsevere community acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001; 161: 1866–72PubMedCrossRef
122.
Zurück zum Zitat Alvarez FJ, Garciia A, Elias T, et al. Community acquired pneumonia in patients older than 60 years. Incidence of atypical agents and clinical-radiological progression. Med Clin (Barc) 2001; 117: 441–5 Alvarez FJ, Garciia A, Elias T, et al. Community acquired pneumonia in patients older than 60 years. Incidence of atypical agents and clinical-radiological progression. Med Clin (Barc) 2001; 117: 441–5
123.
Zurück zum Zitat Masiai M, Gutieirrez F, Padilla S, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007; 13(2): 153–61 Masiai M, Gutieirrez F, Padilla S, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007; 13(2): 153–61
124.
Zurück zum Zitat Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162: 1849–58PubMedCrossRef Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162: 1849–58PubMedCrossRef
126.
Zurück zum Zitat Mirete JC, Gutieirrez F, Hernandez I, et al. Community-acquired pneumonia associated with influenza virus. Med Clin (Barc) 2002; 118: 622–6 Mirete JC, Gutieirrez F, Hernandez I, et al. Community-acquired pneumonia associated with influenza virus. Med Clin (Barc) 2002; 118: 622–6
127.
Zurück zum Zitat Diaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131: 779–87PubMedCrossRef Diaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131: 779–87PubMedCrossRef
128.
129.
Zurück zum Zitat Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352: 1749–59PubMedCrossRef Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352: 1749–59PubMedCrossRef
130.
Zurück zum Zitat Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251–3PubMed Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251–3PubMed
131.
Zurück zum Zitat Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med 2004; 128: 32–8PubMed Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med 2004; 128: 32–8PubMed
132.
Zurück zum Zitat Loeb M, McGeer A, McArthur M, et al. Risk factors for pneumonia and other respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999; 159: 2058–64PubMedCrossRef Loeb M, McGeer A, McArthur M, et al. Risk factors for pneumonia and other respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999; 159: 2058–64PubMedCrossRef
133.
Zurück zum Zitat Vergis EN, Brennen C, Wagener M, et al. Pneumonia in longterm care: a prospective case-control study of risk factors and impact on survival. Arch Intern Med 2001; 161: 2378–81PubMedCrossRef Vergis EN, Brennen C, Wagener M, et al. Pneumonia in longterm care: a prospective case-control study of risk factors and impact on survival. Arch Intern Med 2001; 161: 2378–81PubMedCrossRef
134.
Zurück zum Zitat Malik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344: 665–71CrossRef Malik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344: 665–71CrossRef
135.
Zurück zum Zitat Morice AH, Lowry R, Brown MJ, et al. Angiotensin-converting enzyme and the cough reflex. Lancet 1987; 2: 1116–8PubMedCrossRef Morice AH, Lowry R, Brown MJ, et al. Angiotensin-converting enzyme and the cough reflex. Lancet 1987; 2: 1116–8PubMedCrossRef
136.
Zurück zum Zitat Sekizawa K, Matsui T, Nakagawa T, et al. ACE inhibitors and pneumonia [letter]. Lancet 1998; 352: 1069PubMedCrossRef Sekizawa K, Matsui T, Nakagawa T, et al. ACE inhibitors and pneumonia [letter]. Lancet 1998; 352: 1069PubMedCrossRef
137.
Zurück zum Zitat Arai T, Yasuda Y, Toshima S, et al. ACE inhibitors and pneumonia in elderly people [letter]. Lancet 1998; 352: 1937–8PubMedCrossRef Arai T, Yasuda Y, Toshima S, et al. ACE inhibitors and pneumonia in elderly people [letter]. Lancet 1998; 352: 1937–8PubMedCrossRef
138.
Zurück zum Zitat van de Garde EM, Souverein PC, van den Bosch JM, et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J 2006; 27: 1217–22PubMedCrossRef van de Garde EM, Souverein PC, van den Bosch JM, et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J 2006; 27: 1217–22PubMedCrossRef
139.
Zurück zum Zitat Teramoto S, Ouchi Y. ACE inhibitors and prevention of aspiration pneumonia in elderly hypertensives [letter]. Lancet 1999; 353: 843PubMedCrossRef Teramoto S, Ouchi Y. ACE inhibitors and prevention of aspiration pneumonia in elderly hypertensives [letter]. Lancet 1999; 353: 843PubMedCrossRef
140.
Zurück zum Zitat Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Am J Respir Crit Care Med 2004; 169: 1041–5PubMedCrossRef Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Am J Respir Crit Care Med 2004; 169: 1041–5PubMedCrossRef
141.
Zurück zum Zitat Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950–5PubMedCrossRef Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950–5PubMedCrossRef
142.
Zurück zum Zitat Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8PubMedCrossRef Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8PubMedCrossRef
143.
Zurück zum Zitat Waterer GW, Buckingham SC, Kessler LA, et al. Decreasing β -lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001. Chest 2003; 124: 519–25PubMedCrossRef Waterer GW, Buckingham SC, Kessler LA, et al. Decreasing β -lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001. Chest 2003; 124: 519–25PubMedCrossRef
144.
Zurück zum Zitat Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965–72PubMedCrossRef Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965–72PubMedCrossRef
145.
Zurück zum Zitat Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 777–90PubMedCrossRef Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 777–90PubMedCrossRef
146.
Zurück zum Zitat Bauer T, Ewig S, Marcos MA, et al. Streptococcus pneumoniae in community-acquired pneumonia: how important is drug resistance? Med Clin North Am 2001; 85: 1367–79PubMedCrossRef Bauer T, Ewig S, Marcos MA, et al. Streptococcus pneumoniae in community-acquired pneumonia: how important is drug resistance? Med Clin North Am 2001; 85: 1367–79PubMedCrossRef
147.
Zurück zum Zitat Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community- acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399–408PubMedCrossRef Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community- acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399–408PubMedCrossRef
148.
Zurück zum Zitat Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002; 113: 120–6PubMedCrossRef Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002; 113: 120–6PubMedCrossRef
149.
Zurück zum Zitat Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630–1PubMedCrossRef Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630–1PubMedCrossRef
150.
Zurück zum Zitat Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008–11PubMedCrossRef Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008–11PubMedCrossRef
151.
Zurück zum Zitat Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–64PubMedCrossRef Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–64PubMedCrossRef
152.
Zurück zum Zitat Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233–9PubMedCrossRef Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233–9PubMedCrossRef
153.
Zurück zum Zitat Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–50PubMedCrossRef Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–50PubMedCrossRef
154.
Zurück zum Zitat Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659–65PubMedCrossRef Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659–65PubMedCrossRef
155.
Zurück zum Zitat Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29: 797–800PubMedCrossRef Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29: 797–800PubMedCrossRef
156.
Zurück zum Zitat Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819–24PubMedCrossRef Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819–24PubMedCrossRef
157.
Zurück zum Zitat Mongkolrattanothai K, Boyle S, Kahana MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37: 1050–8PubMedCrossRef Mongkolrattanothai K, Boyle S, Kahana MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37: 1050–8PubMedCrossRef
158.
Zurück zum Zitat Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562–73PubMedCrossRef Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562–73PubMedCrossRef
159.
Zurück zum Zitat Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436–44PubMedCrossRef Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436–44PubMedCrossRef
160.
Zurück zum Zitat Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: 2732–8PubMedCrossRef Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: 2732–8PubMedCrossRef
161.
Zurück zum Zitat Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288–97PubMedCrossRef Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288–97PubMedCrossRef
162.
Zurück zum Zitat Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160: 3234–40PubMedCrossRef Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160: 3234–40PubMedCrossRef
163.
Zurück zum Zitat Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–24PubMedCrossRef Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–24PubMedCrossRef
164.
Zurück zum Zitat Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240–6PubMedCrossRef Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240–6PubMedCrossRef
165.
Zurück zum Zitat Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857–62PubMedCrossRef Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857–62PubMedCrossRef
166.
Zurück zum Zitat Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052–9PubMedCrossRef Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052–9PubMedCrossRef
167.
Zurück zum Zitat Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701–7PubMedCrossRef Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701–7PubMedCrossRef
168.
Zurück zum Zitat Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36: 1132–8PubMedCrossRef Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36: 1132–8PubMedCrossRef
169.
Zurück zum Zitat Anderson KB, Tan JS, File Jr TM, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376–81PubMedCrossRef Anderson KB, Tan JS, File Jr TM, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376–81PubMedCrossRef
170.
Zurück zum Zitat Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–52PubMedCrossRef Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–52PubMedCrossRef
171.
Zurück zum Zitat Goldstein EJ, Citron DM, Warren YA, et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148–55PubMedCrossRef Goldstein EJ, Citron DM, Warren YA, et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148–55PubMedCrossRef
172.
Zurück zum Zitat Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997. Am J Med 1999; 107(1A): 34S–43SPubMedCrossRef Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997. Am J Med 1999; 107(1A): 34S–43SPubMedCrossRef
173.
Zurück zum Zitat Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440–4PubMedCrossRef Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440–4PubMedCrossRef
174.
Zurück zum Zitat Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 589–93PubMed Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 589–93PubMed
175.
Zurück zum Zitat Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446–52PubMedCrossRef Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446–52PubMedCrossRef
176.
Zurück zum Zitat Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420–6PubMedCrossRef Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420–6PubMedCrossRef
177.
Zurück zum Zitat Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576–80PubMedCrossRef Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576–80PubMedCrossRef
178.
Zurück zum Zitat Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123: 1503–11PubMedCrossRef Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123: 1503–11PubMedCrossRef
179.
Zurück zum Zitat Gleason PP, Meehan TP, Fine JM, et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562–72PubMedCrossRef Gleason PP, Meehan TP, Fine JM, et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562–72PubMedCrossRef
180.
Zurück zum Zitat Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81PubMedCrossRef Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81PubMedCrossRef
181.
Zurück zum Zitat Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia. Clin Ther 2005; 27: 1251–9PubMedCrossRef Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia. Clin Ther 2005; 27: 1251–9PubMedCrossRef
182.
Zurück zum Zitat Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172–83PubMedCrossRef Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172–83PubMedCrossRef
183.
Zurück zum Zitat Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22PubMedCrossRef Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22PubMedCrossRef
184.
Zurück zum Zitat Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 1438–44PubMedCrossRef Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 1438–44PubMedCrossRef
185.
Zurück zum Zitat Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709PubMedCrossRef Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709PubMedCrossRef
186.
Zurück zum Zitat Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12–9PubMedCrossRef Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12–9PubMedCrossRef
187.
Zurück zum Zitat Ely EW, Angus DC, Williams MD, et al. Treatment of older patients with severe sepsis using drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 187–95PubMedCrossRef Ely EW, Angus DC, Williams MD, et al. Treatment of older patients with severe sepsis using drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 187–95PubMedCrossRef
188.
Zurück zum Zitat Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952–61PubMedCrossRef Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952–61PubMedCrossRef
189.
Zurück zum Zitat Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 50–8PubMedCrossRef Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 50–8PubMedCrossRef
190.
Zurück zum Zitat Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862–71PubMedCrossRef Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862–71PubMedCrossRef
191.
Zurück zum Zitat Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963–8PubMedCrossRef Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963–8PubMedCrossRef
192.
Zurück zum Zitat Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800PubMedCrossRef Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800PubMedCrossRef
193.
Zurück zum Zitat Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–9PubMedCrossRef Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–9PubMedCrossRef
194.
Zurück zum Zitat Cohen AT, Gallus AS, Lassen MR, et al. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS) [abstract]. J Thromb Haemost 2003; 1 Suppl.: 2046CrossRef Cohen AT, Gallus AS, Lassen MR, et al. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS) [abstract]. J Thromb Haemost 2003; 1 Suppl.: 2046CrossRef
195.
Zurück zum Zitat Wenger NK. Early ambulation after myocardial infarction: the in-patient exercise program. Clin Sports Med 1984; 3: 333–48PubMed Wenger NK. Early ambulation after myocardial infarction: the in-patient exercise program. Clin Sports Med 1984; 3: 333–48PubMed
196.
Zurück zum Zitat Munin MC. Early inpatient rehabilitation after elective hip and knee arthroplasty. JAMA 1998; 279: 847–52PubMedCrossRef Munin MC. Early inpatient rehabilitation after elective hip and knee arthroplasty. JAMA 1998; 279: 847–52PubMedCrossRef
197.
Zurück zum Zitat Mundy LM, Leet TL, Darst K, et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124: 883–9PubMedCrossRef Mundy LM, Leet TL, Darst K, et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124: 883–9PubMedCrossRef
198.
Zurück zum Zitat Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia. JAMA 1998; 279: 1452–7PubMedCrossRef Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia. JAMA 1998; 279: 1452–7PubMedCrossRef
199.
Zurück zum Zitat Rhew DC, Riedinger MS, Sandhu M, et al. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998; 114: 115–9PubMedCrossRef Rhew DC, Riedinger MS, Sandhu M, et al. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998; 114: 115–9PubMedCrossRef
200.
Zurück zum Zitat Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449–54PubMedCrossRef Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449–54PubMedCrossRef
201.
Zurück zum Zitat Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians’ decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599–605PubMedCrossRef Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians’ decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599–605PubMedCrossRef
202.
Zurück zum Zitat Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278–84PubMedCrossRef Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278–84PubMedCrossRef
203.
Zurück zum Zitat Menéindez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783–90CrossRef Menéindez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783–90CrossRef
204.
Zurück zum Zitat Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6PubMedCrossRef Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6PubMedCrossRef
205.
Zurück zum Zitat Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752–60PubMedCrossRef Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752–60PubMedCrossRef
206.
Zurück zum Zitat Rubins JB, Alter M, Loch J, et al. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999; 67: 5979–84PubMed Rubins JB, Alter M, Loch J, et al. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999; 67: 5979–84PubMed
207.
Zurück zum Zitat Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747–55PubMedCrossRef Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747–55PubMedCrossRef
208.
Zurück zum Zitat Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people: Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399–403PubMedCrossRef Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people: Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399–403PubMedCrossRef
209.
Zurück zum Zitat Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43: 860–8PubMedCrossRef Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43: 860–8PubMedCrossRef
210.
Zurück zum Zitat Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003; 163: 1089–94PubMedCrossRef Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003; 163: 1089–94PubMedCrossRef
211.
Zurück zum Zitat Ortqvist A, Granath F, Askling J, et al. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur Respir J 2007; 30: 414–22PubMedCrossRef Ortqvist A, Granath F, Askling J, et al. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur Respir J 2007; 30: 414–22PubMedCrossRef
212.
Zurück zum Zitat Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–32PubMedCrossRef Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–32PubMedCrossRef
213.
Zurück zum Zitat Voordouw BC, Sturkenboom MC, Dieleman JP, et al. Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. Arch Intern Med 2006; 166: 1980–5PubMedCrossRef Voordouw BC, Sturkenboom MC, Dieleman JP, et al. Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. Arch Intern Med 2006; 166: 1980–5PubMedCrossRef
214.
Zurück zum Zitat Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363–8PubMedCrossRef Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363–8PubMedCrossRef
215.
Zurück zum Zitat Nathwani D, Rubinstein E, Barlow G, et al. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001; 32: 728–41PubMedCrossRef Nathwani D, Rubinstein E, Barlow G, et al. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001; 32: 728–41PubMedCrossRef
216.
Zurück zum Zitat Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350–6PubMedCrossRef Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350–6PubMedCrossRef
217.
Zurück zum Zitat Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 2003; 115: 343–51PubMedCrossRef Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 2003; 115: 343–51PubMedCrossRef
218.
Zurück zum Zitat Chu LA, Bratzler DW, Lewis RJ, et al. Improving the quality of care for patients with pneumonia in very small hospitals. Arch Intern Med 2003; 163: 326–32PubMedCrossRef Chu LA, Bratzler DW, Lewis RJ, et al. Improving the quality of care for patients with pneumonia in very small hospitals. Arch Intern Med 2003; 163: 326–32PubMedCrossRef
Metadaten
Titel
Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia
verfasst von
Dr Félix Gutiérrez
Mar Masiá
Publikationsdatum
01.07.2008
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 7/2008
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825070-00005

Weitere Artikel der Ausgabe 7/2008

Drugs & Aging 7/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.